FC084CSA

FC084CSA is an orally bioavailable small molecule inhibitor that selectively targets the **AXL receptor tyrosine kinase**. By binding to and inhibiting AXL activation, it has potential immunostimulating and antineoplastic (anti-cancer) activities. The drug is being developed primarily for the treatment of advanced malignant solid tumors, including breast cancer and liver cancer. Preclinical rationale includes its ability to modulate the tumor microenvironment—particularly in patients with STK11 mutations who are less responsive to immunotherapy due to elevated AXL expression. Clinical studies have shown that FC084CSA is well tolerated in heavily pretreated patients with advanced solid tumors, with most adverse events being mild or moderate in severity[1][2][3]. The developer of this drug is Zhongshan Medical Novishen New Drug R & D Co., Ltd., with active clinical development also involving FindCure Biosciences (ZhongShan) Co., Ltd.[3].